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The aim of this review is to describe the contributions of the knowledge of T-cell responses to the understanding of 
the physiopathology and the responsiveness to etiological treatment during the chronic phase of Chagas disease. T-
helper (Th)1 and interleukin (IL)-10 Trypanosoma cruzi-specific T-cells have been linked to the asymptomatic phase 
or to severe clinical forms of the disease, respectively or vice versa, depending on the T. cruzi antigen source, the 
patient’s location and the performed immunological assays. Parasite-specific T-cell responses are modulated after 
benznidazole (BZ) treatment in chronically T. cruzi-infected subjects in association with a significant decrease in T. 
cruzi-specific antibodies. Accumulating evidence has indicated that treatment efficacy during experimental infection 
with T. cruzi results from the combined action of BZ and the activation of appropriate immune responses in the host. 
However, strong support of this interaction in T. cruzi-infected humans remains lacking. Overall, the quality of T-cell 
responses might be a key factor in not only disease evolution, but also chemotherapy responsiveness. Immunological 
parameters are potential indicators of treatment response regardless of achievement of cure. Providing tools to moni-
tor and provide early predictions of treatment success will allow the development of new therapeutic options.
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Chagas disease, which is caused by the intracellular 
protozoan parasite Trypanosoma cruzi, affects approxi-
mately six-seven million people from southern California 
to South America and Western Europe (Bern et al. 2007, 
WHO 2015). In 20-30% of infected individuals, this dis-
ease results in heart disease or megaoesophagus/megaco-
lon, making Chagas disease the most common cause of 
infectious myocarditis worldwide (Feldman & McNamara 
2000). Early investigations suggested that Chagas disease 
had an autoimmune aetiology. However, an emerging con-
sensus has indicated that the persistence of parasites might 
lead to immune exhaustion and altered host immunoregu-
lation, which might be responsible for cumulative tissue 
damage in chronic Chagas disease (Tarleton 2003, Laucel-
la et al. 2004, Albareda et al. 2006, Gutierrez et al. 2009).
Chemotherapy with nifurtimox or benznidazole (BZ) 
is recommended during both acute and early chronic 
phases of T. cruzi infection (de Andrade et al. 1996, So-
sa-Estani et al. 1998). Several studies have also demon-
strated the benefits of chemotherapy with BZ in adults 
with chronic T. cruzi infection (Viotti et al. 1994, Fabbro 
et al. 2007). Based on this evidence, experts advocate 
that treatment in adults without advanced heart disease 
should generally be offered (Bern et al. 2007).
In spite of these latter findings, treatment during 
the chronic phase of T. cruzi infection remains limited 
primarily because of the lack of early metrics of treat-
ment efficacy and the potential adverse effects of these 
therapeutics (Viotti et al. 2009).
Due to the low levels of parasitaemia in subjects with 
chronic T. cruzi infections, direct detection of T. cruzi or its 
products or constituents (e.g., DNA, proteins) (Cerisola et 
al. 1971, Zulantay et al. 2004) is inadequate for determin-
ing the effectiveness of treatment, but is useful primarily 
for indicating treatment failure (Duffy et al. 2013). The pri-
mary criterion of a positive response to treatment has been 
the complete loss of reactivity in serially performed con-
ventional serological tests (i.e., ELISA, haemagglutination 
and immunofluorescence), as well as the lack of progres-
sion to more severe clinical symptoms of Chagas disease. 
However, the decrease in serological titres using current 
standard tests is extremely slow, requiring five-10 years to 
achieve conversion to negative serology in even a fraction 
of treated adult subjects (Viotti et al. 2006, Bertocchi et al. 
2013). Disease progression also occurs over decades and 
does not occur in all infected individuals, irrespective of 
treatment (Viotti et al. 2005, Fabbro et al. 2007).
The low percentages of complete seronegative con-
version after specific chemotherapy in subjects with 
long-term chronic T. cruzi infections have led to the most 
likely inaccurate idea that treatment during the chronic 
phase is useless. Here, we review the contributions of 
the knowledge of T-cell responses to the understanding 
of how treatment works with the aim of providing new 
tools to monitor and predict treatment success during 
the chronic phase of T. cruzi infection.
Function and phenotype of T-cells responsive to 
T. cruzi antigens 
The original goals of the studies from our group were 
to better understand T-cell responses to T. cruzi in chron-
ically infected subjects and to correlate these responses 
with cardiac disease severity. The frequency, phenotype 
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and function of T-cells responsive to T. cruzi antigens 
were measured in adults (30-70 years of age) and children 
(5-16 years of age) with chronic Chagas disease living 
in areas nonendemic for T. cruzi infection in Argentina. 
The primary findings included an overall low level of de-
tectable T. cruzi-specific T-cells and the predominance 
of single cytokine [interferon (IFN)-γ only]-producing 
T-cells in the circulation of adult subjects with long-term 
T. cruzi infections (Alvarez et al. 2008) (Table I). Con-
versely, children presumed to have shorter-term infec-
tions showed parasite-specific T-cell responses that were 
more robust and more highly functional (Albareda et al. 
2013) (Table I). The simultaneous secretion of IFN-γ and 
interleukin (IL)-2 was prevalent among T. cruzi-infected 
children (Albareda et al. 2013), while monofunctional re-
sponses were higher in T. cruzi-infected adults compared 
with infected children (Albareda et al. 2006, Alvarez et 
al. 2008) (Table I). Polyfunctional T-cell responses are 
important because these cells are optimised for effector 
function, including higher IFN-γ secretion on a per-cell 
basis, more efficient killing by IFN-γ and tumour necro-
sis factor (TNF)-α compared with either cytokine alone 
and IL-2-mediated expansion of T-cells in an autocrine or 
paracrine manner, which could enhance T-cell memory 
function (Seder et al. 2008, Virgin et al. 2009).
Other authors have also reported that children in the 
early phase of chronic T. cruzi infection exhibit IFN-γ 
and TNF-α-secreting CD4+ T-cells in response to T. cruzi 
antigens (Samudio et al. 1998, Sathler-Avelar et al. 2006); 
however, these responses were associated with IL-10 pro-
duction by CD4+ T-cells (Sathler-Avelar et al. 2006). There-
fore, the maintenance of functional T-cells is proposed to 
control parasite replication without the induction of tissue 
damage and these responses appear to be impaired with 
the length of the infection. IL-10 might counteract T-helper 
(Th)1 responses, which, if sustained overtime, might be 
deleterious for the host (Dutra & Gollobb 2008).
Because phenotypic defects in T-cells might arise 
along with functional ability loss, the phenotypic profile of 
T. cruzi-specific T-cells has also been evaluated in chronic 
Chagas disease patients. The pool of parasite-specific IFN-
γ-producing CD4+ T-cells is primarily composed of CD122 
(the common beta chain of IL-2 and IL-15 receptors) low 
and chemokine receptor 7 low T-cells, while some of these 
cells express CD127 (the homeostatic IL-7 receptor), which 
is consistent with effector memory T-cells (TEMs) (Fig-
ure). TEMs that are characteristic of persistent infections 
have low proliferative capacity and primarily migrate to 
peripheral tissues; however, in contrast to effector T-cells, 
TEMs may persist in the host. Furthermore, a fraction of 
T. cruzi-specific T-cells exhibit low expression levels of 
killer cell lectin-like receptor (KLRG)1, CD57 and leuko-
cyte immunoglobulin-like receptor (LIR)-1 (Argüello et 
al. 2012), while T-cells expressing the costimulation mol-
ecules CD27 and CD28 are enriched (Figure) (Albareda et 
al. 2006, 2009). Considering that KLRG1 and CD57 ex-
pression increases with the rounds of antigen stimulation 
and that CD27 and CD28 expression is down-regulated 
(Appay et al. 2008) while LIR-1 expression is up-regulated 
during T-cell differentiation (Antrobus et al. 2005), these 
findings indicate that naïve CD4+ T-cells may also be re-
cruited for T-cell responses in chronically infected sub-
jects. Long-term infection with T. cruzi also results in the 
up-regulation of cytotoxic T lymphocyte antigen-4 (Fig-
ure) (Argüello et al. 2012) likely as part of a homeostatic 
process to control tissue damage, although this up-regula-
tion might damper T-cell responses. The above-described 
findings are compatible with immune exhaustion, which 
has described for other chronic parasitic and viral infec-
tions (Gigley et al. 2012, Rodrigues et al. 2014).
Phenotypic characterization of Trypanosma cruzi-specif CD4+ T-cells 
in chronically infected subjects. Peripheral blood mononuclear cells 
from eight patients were stimulated with 15 ug/mL of T. cruzi lysate 
from the Brazil strain for 16-20 h. CD4+interferon (IFN)-γ+ T-cells 
were selected and analysed for the expression of CD127, chemokine 
receptor (CCR)7, CD122, killer cell lectin-like receptor (KLRG)1, 
CD27, CD28, CD57, immunoglobulin-like receptor (LIR)-1 and cy-
totoxic T lymphocyte antigen (CTLA)-4 by flow cytometry. Means 
values ± standard deviation are shown.
TABLE I
Trypanosoma cruzi-specific T-cell responses in children and 
adults with Chagas disease living in nonendemic areas of 
Argentina measured by interferon (IFN)-γ and  
interleukin (IL)-2 ELISPOT
Positive ELISPOT  
responses to T. cruzi lysate
Positive responders/total T. cruzi-
infected subjects evaluated
n/n (%)
Children Adults
IFN-γ + IL-2 10/17 (58.8)a,b 4/22 (18)
IFN-γ-only 3/17 (17.6)c 11/22 (50)
IL-2-only 0/17 (0) 0/22 (0)
a: Fisher exact test p = 0.0181 vs. percentage of IFN-γ-only 
responders in T. cruzi-infected children; b: p < 0.02 vs. per-
centage of IFN-γ + IL-2 in adults; c: p < 0.05 vs. percentage of 
IFN-γ-only in adults.
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Notably, dissimilar findings have been reported re-
garding the association of IFN-γ and IL-10 production in 
response to T. cruzi antigens with disease severity dur-
ing the chronic phase of infection in adult subjects (Table 
II). In contrast to our findings, increased IFN-γ produc-
tion after stimulating peripheral blood mononuclear cells 
(PBMCs) with T. cruzi antigens was observed in patients 
with severe cardiomyopathy compared to seropositive 
subjects with no signs of cardiac disease (Abel et al. 2001, 
Guedes et al. 2012), whereas IL-10 production was either 
detected in asymptomatic patients (Guedes et al. 2012, 
Gomes et al. 2014) or undetectable (Abel et al. 2001) 
(Table II). Similarly, patients with severe cardiomyopathy 
had higher frequencies of CD3+ or CD4+ T-cells, includ-
ing CD4+Foxp3+CD25hi T-cells with the ability to secrete 
IFN-γ in response to T. cruzi antigens (Gomes et al. 2003, 
Cuellar et al. 2009, de Araújo et al. 2012), whereas IL-10
-secreting cells were found primarily during the asymp-
tomatic phase (Gomes et al. 2003) or detected in all clinical 
groups (de Araújo et al. 2012). In a recent study focused 
on Chagas disease patients with severe cardiomyopathy, 
increased levels of IFN-γ and IL-10 specific for T. cruzi 
antigens have been reported (Longhi et al. 2014).
In contrast to these findings, comparable frequencies 
of CD4+ T-cells producing IFN-γ and IL-10 were reported 
in patients with no signs of cardiac disease and those with 
severe cardiomyopathy (Fiuza et al. 2009). Stimulating 
PBMCs with cytoplasmatic repetitive antigen (Lafaille 
1989, Kriegger 1992) induced IFN-γ, IL-4 and TNF-α 
production by CD4+ T-cells in patients with or without 
cardiac disease (Lorena et al. 2010). Additionally, only 
subjects in the indeterminate phase of Chagas disease 
presented higher frequencies of CD4+IL-10+ T-cells com-
pared with uninfected controls; however, these levels did 
not differ from those found in patients with severe car-
diomyopathy. In contrast, when flagellar repetitive anti-
gen (Lafaille et al. 1989, Kriegger et al. 1992) was used 
as the antigen source, CD4+IL10+ T-cells were detected 
in both patients in the indeterminate phase of the disease 
and those presenting cardiomyopathy, while the frequen-
cies of CD4+IFN-γ+ T-cells remained unaltered compared 
with uninfected controls (Lorena et al. 2010).
In another study, de Melo et al. (2012) reported that 
most patients in the indeterminate phase of the infection 
displayed increased IFN-γ gene expression after stimu-
lation with T. cruzi antigens, while the majority of pa-
tients with cardiomyopathy had high levels of IL-10.
The use of soluble parasite antigens vs. in vitro infec-
tion might also lead to different results. In fact, Gomes 
et al. (2012) recently demonstrated that the short-term in 
vitro culture of whole blood samples with live T. cruzi 
parasites led to increased IFN-γ+ and IL-10+ lymphocytes 
in subjects with no sign of cardiac disease compared 
with those with severe cardiomyopathy, in contrast to 
previous reports from the same group showing increased 
levels of IFN-γ upon stimulation with an epimastigote/
trypomastigote lysate (Gomes et al. 2003).
Little information is available regarding CD8+ T-cell 
responses in subjects with chronic T. cruzi infection pri-
marily because the complexity of the T. cruzi genome has 
made it difficult to identify individual targets of CD8+ R
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T-cell responses in T. cruzi-infected subjects. In an at-
tempt to identify and quantify T-cell responses to defined 
T. cruzi epitopes, we tested human leukocyte antigen 
(HLA)-A2.1-restricted CD8+ T-cell responses (HLA-A2.1 
is one of the most common class I alleles in this popula-
tion) to several trans-sialidase-derived epitopes using a 
combination of HLA-A2 tetramers, ELISPOT analysis 
and intracellular cytokine staining assays (Martin et al. 
2006, Alvarez et al. 2008) (Table II). The percentage of 
responders strongly correlated with disease severity, with 
60% of individuals in the indeterminate phase, but only 
22% of the subjects with cardiomyopathy responding to 
trans-sialidase peptides (Alvarez et al. 2008). When CD8+ 
T-cell responses were measured using T. cruzi-infected 
autologous dendritic cells, we observed that subjects with 
less severe forms of the cardiac disease were more likely 
to mount T. cruzi-specific IFN-γ responses than subjects 
with severe cardiomyopathy (Albareda et al. 2006) (Table 
II). HLA-A201-restricted epitopes derived from kineto-
plastid membrane protein (KMP)-11 (Diez et al. 2006, 
Lasso et al. 2010), heat shock protein (HSP)-70 (Marañón 
et al. 2011), FL-160 (Fonseca et al. 2005) or cruzipain 
(Fonseca et al. 2005) have also been reported as targets of 
IFN-γ responses by CD8+ T-cells in chronically T. cruzi-
infected subjects (Table II). While no differences in the 
magnitude of T-cell responses specific for KMP-11 and 
HSP-70-derived peptides according to the clinical stage 
of the disease were found, IFN-γ secretion in response to 
HLA-A2.01-restricted paraflagellar rod proteins (PRP)-2 
and PRP-3-derived peptides was higher in patients in the 
indeterminate phase of the infection compared with pa-
tients with cardiac disease (Egui et al. 2012) (Table II). Con-
cerning the phenotype of CD8+ T-cells specific for T. cruzi 
antigens, CD8+IFN-γ+ T-cells predominantly showed an ef-
fector memory phenotype were enriched in CD27+CD28+ 
cells in response to T. cruzi (Albareda et al. 2006).
As a whole, Th1 and IL-10-producing T-cells can be 
detected in the different clinical groups of the chronic 
infection, with a degree of variation according to the T. 
cruzi antigen source, the patient’s location and immu-
nological assays. The quality of T-cell responses might 
determine the pattern of the cellular response and the 
severity of the disease in T. cruzi infection.
Modulation of T. cruzi-specific T-cell responses 
following chemotherapy 
To gain a clearer understanding of the relationship 
between parasite persistence and T. cruzi-specific T-cell 
maintenance during chronic Chagas disease, we examined 
the changes in the frequency of T. cruzi-specific T-cells in 
adult subjects with chronic T. cruzi infection following BZ 
treatment. We showed that the levels of IFN-γ-producing 
T-cells in response to a T. cruzi lysate preparation signifi-
cantly decreased over 12 months following BZ treatment 
and that IFN-γ-secreting T-cells fell below the level of de-
tection by 36 months post-treatment (Laucella et al. 2009), 
along with a significant drop in antibody levels specific 
for a set of recombinant proteins (Laucella et al. 2009, Vi-
otti et al. 2011) as determined by multiplex serological as-
says (Cooley et al. 2008), in 15 of 32 (47%) patients. This 
latter assay appeared to be more sensitive than conven-
tional serological tests in detecting changes in antibody 
levels following BZ treatment. Surprisingly, a proportion 
of BZ-treated, but not untreated, subjects exhibited an 
initial increase in IFN-γ responses before the decrease at 
12 months post-treatment (Laucella et al. 2009). We hy-
pothesise that this transient rise in IFN-γ-secreting T-cells 
might be triggered by a release of parasite antigens due to 
BZ-induced parasite death and might enhance the parasiti-
cidal effect of the drug. The most straightforward interpre-
tation of these results is that BZ treatment decreases the 
parasite load, thus diminishing the antigen that is required 
to maintain the T. cruzi-specific effector T-cells.
Other studies have measured T-cells responsive to T. 
cruzi antigens after BZ treatment in subjects with chron-
ic T. cruzi infection. Of note, these studies focused on 
the comparison of subjects treated with BZ with those 
untreated or uninfected; however, these comparisons 
were not pre-treatment/post-treatment comparisons. A 
shift towards a type two-modulated profile with a higher 
level of IL-10 production was found in the CD4+ T-cell 
compartment, whereas high IFN-γ expression was ob-
served in CD8+ T-cells of T. cruzi-infected children after 
one year of BZ treatment (Sathler-Avelar et al. 2008). 
Likewise, the treatment of chronically T. cruzi-infected 
adult subjects with no signs of cardiac disease led to in-
creased levels of TNF-α+CD8+ and IFN-γ+CD8+ T-cells 
(Sathler-Avelar et al. 2012) with unchanged frequencies 
of CD4+IL-17+ T-cells (Guedes et al. 2012) in response to 
T. cruzi antigens. Subjects with chronic T. cruzi infec-
tion who were treated with BZ 14-30 years earlier and 
achieved serological cure showed higher levels of IFN-γ 
production specific for T. cruzi compared with patients 
who had not been cured (Bahia-Oliveira et al. 2000).
In a mouse model of acute and chronic T. cruzi in-
fections, BZ treatment resulted in the emergence of T. 
cruzi-specific central memory T-cells (Bustamante et al. 
2008). A reduction in the total numbers of activated and 
TEMs after the treatment of infected mice has also been 
shown (Fernández et al. 2009). A positive treatment out-
come was demonstrated by the observation that treated 
animals were protected against re-infection (Olivieri et 
al. 2002). Altogether, changes in T. cruzi-specific T-cell 
responses can be potential early indicators of treatment 
response, even in cases in which cure is not achieved. 
Long-term monitoring of T-cell responses following 
chemotherapy in relation to the serological evolution by 
conventional serology, which is currently the only gold 
standard of treatment efficacy in Chagas disease, will 
allow the usefulness of immunological parameters as 
surrogate markers of treatment efficacy to be validated.
Immunocompetence as a factor of treatment 
efficacy in T. cruzi infection 
The immunological status of the host might also be a 
determining factor of treatment success. In this respect, a 
relationship between treatment success and the immune 
status pre-therapy has been demonstrated in human im-
munodeficiency virus positive subjects under highly ac-
tive antiretroviral therapy (Marchetti et al. 2012).
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That the immune response can be a key factor in 
the efficacy of treatment against T. cruzi has been 
documented in experimental acute T. cruzi infections; 
however, strong support of this correlation in T. cruzi-
infected humans remains lacking. In a murine model 
of T. cruzi infection, treating IFN-γ, IL-12, protein, 
55-TNF receptor and inducible nitric oxide synthase 
knockout mice with BZ reduced the cure rates to 42%, 
35% and 28%, respectively, compared with wild-type 
animals (Romanha et al. 2002). The absence of CD4+ T-
cells dramatically affected the efficacy of BZ treatment, 
whereas parasitaemia and cure rates were less affected 
by the absence of CD8+ T-cells and B cells (Ferraz et 
al. 2009). The administration of blocking antibodies for 
IL-12 or IFN-γ concomitant with a suboptimal dose of 
BZ enhanced parasitaemia and accelerated mortality, 
while treatment efficacy did not change in mice treated 
with optimal doses of BZ (Michailowsky et al. 1998). 
Simultaneous treatment with a suboptimal dose of BZ 
and recombinant IL-12 enhanced the efficacy of drug 
treatment as measured by parasitaemia levels and mouse 
survival (Michailowsky et al. 1998).
Likewise, BZ treatment during experimental T. cruzi 
infection in mice enhanced phagocytosis, parasite de-
struction and cytokine release by macrophages (Murta 
et al. 1999) and led to a partial reversion of spleen and 
lymph node enlargement observed in T. cruzi-infected 
untreated mice (Olivieri et al. 2006). These findings 
support the notion that drug treatment responsiveness 
results from the combined action of the drug and the ac-
tivation of appropriate immune responses in the host.
Future directions 
A throughout knowledge of how drug treatment 
works might provide guidance regarding how to most 
effectively treat and monitor therapy outcomes in chron-
ically T. cruzi-infected individuals. Providing tools to 
not only monitor, but also provide early predictions of 
treatment success or failure will allow the development 
of new therapeutic options. The notion that improving 
host immune responses to T. cruzi could enhance treat-
ment efficacy remains unexplored in T. cruzi-infected 
subjects and deserves future research.
REFERENCES
Abel LC, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, 
Bocchi EA, Teixeira HC, Mady C, Kalil J, Cunha-Neto E 2001. 
Chronic Chagas disease cardiomyopathy patients display an in-
creased IFN-gamma response to Trypanosoma cruzi infection. 
J Autoimmun 17: 99-107.
Albareda MC, de Rissio AM, Tomas G, Serjan A, Alvarez MG, Viotti 
R, Fichera LE, Esteva MI, Potente D, Armenti A, Tarleton RL, 
Laucella SA 2013. Polyfunctional T-cell responses in children 
in early stages of chronic Trypanosoma cruzi infection contrast 
with monofunctional responses of long-term infected adults. 
PLoS Negl Trop Dis 7: e2575.
Albareda MC, Laucella SA, Alvarez MG, Armenti AH, Bertochi G, 
Tarleton RL, Postan M 2006. Trypanosoma cruzi modulates the 
profile of memory CD8+ T cells in chronic Chagas disease pa-
tients. Int Immunol 18: 465-471.
Albareda MC, Olivera GC, Laucella SA, Alvarez MG, Fernandez 
ER, Lococo B, Viotti R, Tarleton RL, Postan M 2009. Chronic 
human infection with Trypanosoma cruzi drives CD4+ T-cells to 
immune senescence. J Immunol 183: 4103-4108.
Alvarez MG, Postan M, Weatherly DB, Albareda MC, Sidney J, Sette 
A, Olivera C, Armenti AH, Tarleton RL, Laucella SA 2008. HLA 
class ccI-T-cell epitopes from trans-sialidase proteins reveal 
functionally distinct subsets of CD8+ T cells in chronic Chagas 
disease. PLoS Negl Trop Dis 2: e288.
Antrobus RD, Khan N, Hislop AD, Montamat-Sicotte D, Garner LI, 
Rickinson AB, Moss PA, Willcox BE 2005. Virus-specific cytotoxic 
T lymphocytes differentially express cell-surface leukocyte immu-
noglobulin-like receptor-1, an inhibitory receptor for class I major 
histocompatibility complex molecules. J Infect Dis 191: 1842-1853.
Appay V, van Lier RA, Sallusto F, Roederer M 2008. Phenotype and 
function of human T lymphocyte subsets: consensus and issues. 
Cytometry A 73: 975-983.
Argüello RJ, Albareda MC, Alvarez MG, Bertocchi G, Armenti AH, 
Vigliano C, Meckert PC, Tarleton RL, Laucella SA 2012. Inhibi-
tory receptors are expressed by Trypanosoma cruzi-specific ef-
fector T-cells and in hearts of subjects with chronic Chagas dis-
ease. PLoS ONE 7: e35966.
Bahia-Oliveira LM, Gomes JA, Cançado JR, Ferrari TC, Lemos EM, 
Luz ZM, Moreira MC, Gazzinelli G, Correa-Oliveira R 2000. 
Immunological and clinical evaluation of chagasic patients sub-
jected to chemotherapy during the acute phase of Trypanosoma 
cruzi infection 14-30 years ago. J Infect Dis 182: 634-638.
Bern C, Montgomery SP, Herwaldt BL, Rassi Jr A, Marin-Neto JA, 
Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, 
Gilman RH, Reyes PA, Salvatella R, Moore AC 2007. Evaluation 
and treatment of Chagas disease in the United States: a system-
atic review. JAMA 298: 2171-2181.
Bertocchi GL, Vigliano CA, Lococo BG, Petti MA, Viotti RJ 2013. 
Clinical characteristics and outcome of 107 adult patients with 
chronic Chagas disease and parasitological cure criteria. Trans R 
Soc Trop Med Hyg 107: 372-376.
Bustamante JM, Bixby LM, Tarleton RL 2008. Drug-induced cure 
drives conversion to a stable and protective CD8+ T central mem-
ory response in chronic Chagas disease. Nat Med 14: 542-550.
Cerisola JA, Alvarez M, Bock M, Wegner D 1971. A comparison of a new 
antigen from amastigotes of Trypanosoma cruzi and an antigen from 
epimastigotes for the diagnosis of Chagas disease by the indirect im-
munofluorescence test. Rev Inst Med Trop Sao Paulo 13: 162-166.
Cooley G, Etheridge RD, Boehlke C, Bundy B, Weatherly DB, Min-
ning T, Haney M, Postan M, Laucella S, Tarleton RL 2008. High 
throughput selection of effective serodiagnostics for Trypano-
soma cruzi infection. PLoS Negl Trop Dis 2: e316.
Cuellar A, Rojas F, Bolaños N, Diez H, Thomas MDC, Rosas F, Ve-
lasco V, López MC, González JM, Puerta C 2009. Natural CD4 
(+) T-cell responses against Trypanosoma cruzi KMP-11 protein 
in chronic chagasic patients. Immunol Cell Biol 87: 149-153.
de Andrade AL, Zicker F, de Oliveira RM, Silva SA, Luquetti A, Travas-
sos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM 
1996. Randomised trial of efficacy of benznidazole in treatment of 
early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
de Araújo FF, Corrêa-Oliveira R, Rocha MO, Chaves AT, Fiuza JA, 
Fares RC, Ferreira KS, Nunes MC, Keesen TS, Damasio MP, Teix-
eira-Carvalho A, Gomes JA 2012. Foxp3+CD25 (high) CD4+ regu-
latory T-cells from indeterminate patients with Chagas disease can 
suppress the effector cells and cytokines and reveal altered correla-
tions with disease severity. Immunobiology 217: 768-777.
de Melo AS, de Lorena VM, Braz SCM, Docena C, Gomes YM 2012. 
IL-10 and IFN-γ gene expression in chronic Chagas disease pa-
tients after in vitro stimulation with recombinant antigens of 
Trypanosoma cruzi. Cytokine 58: 207-212.
420 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 110(3), May 2015
Diez H, López MC, Thomas MDC, Guzmán F, Rosas F, Velazco V, 
González JM, Puerta C 2006. Evaluation of IFN-gamma produc-
tion by CD8 T lymphocytes in response to the K1 peptide from 
KMP-11 protein in patients infected with Trypanosoma cruzi. 
Parasite Immunol 28: 101-105.
Duffy T, Cura CI, Ramirez JC, Abate T, Cayo NM, Parrado R, Bello 
ZD, Velazquez E, Muñoz-Calderon A, Juiz NA, Basile J, Gar-
cia L, Riarte A, Nasser JR, Ocampo SB, Yadon ZE, Torrico F, 
de Noya BA, Ribeiro I, Schijman AG 2013. Analytical perform-
ance of a multiplex real-time PCR assay using TaqMan probes 
for quantification of Trypanosoma cruzi satellite DNA in blood 
samples. PLoS Negl Trop Dis 7: e2000.
Dutra WO, Gollobb KJ 2008. Current concepts in immunoregulation 
and pathology of human Chagas disease. Curr Opin Infect Dis 
21: 287-292.
Egui A, Thomas MC, Morell M, Marañón C, Carrilero B, Segovia M, 
Puerta CJ, Pinazo MJ, Rosas F, Gascón J, López MC 2012. Trypano-
soma cruzi paraflagellar rod proteins 2 and 3 contain immunodomi-
nant CD8 (+) T-cell epitopes that are recognized by cytotoxic T-cells 
from Chagas disease patients. Mol Immunol 52: 289-298.
Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Ami-
cone NA 2007. Trypanocide treatment among adults with chronic 
Chagas disease living in Santa Fe city (Argentina) over a mean 
follow-up of 21 years: parasitological, serological and clinical 
evolution. Rev Soc Bras Med Trop 40: 1-10.
Feldman AM, McNamara D 2000. Myocarditis. N Engl J Med 343: 
1388-1398.
Fernández MC, Cappa SMG, Solana ME 2009. Trypanosoma cruzi: 
immunological predictors of benznidazole efficacy during ex-
perimental infection. Exp Parasitol 124: 172-180.
Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ 2009. 
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes or B lym-
phocytes has different effects on the efficacy of posaconazole and 
benznidazole in treatment of experimental acute Trypanosoma 
cruzi infection. Antimicrob Agents Chemother 53: 174-179.
Fiuza JA, Fujiwara RT, Gomes JA, Rocha MO, Chaves AT, de Araújo 
FF, Fares RC, Teixeira-Carvalho A, Martins-Filho OA, Cançado 
GG, Correa-Oliveira R 2009. Profile of central and effector mem-
ory Tcells in the progression of chronic human Chagas disease. 
PLoS Negl Trop Dis 3: e512.
Fonseca SG, Moins-Teisserenc H, Clave E, Ianni B, Nunes VL, Mady 
C, Iwai LK, Sette A, Sidney J, Marin ML, Goldberg AC, Guil-
herme L, Charron D, Toubert A, Kalil J, Cunha-Neto E 2005. 
Identification of multiple HLA-A*0201-restricted cruzipain and 
FL-160 CD8+ epitopes recognized by T-cells from chronically 
Trypanosoma cruzi-infected patients. Microbes Infect 7: 688-697.
Gigley JP, Bhadra R, Moretto MM, Khan IA 2012. T-cell exhaustion 
in protozoan disease. Trends Parasitol 28: 377-384.
Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, 
Gazzinelli G, Correa-Oliveira R 2003. Evidence that develop-
ment of severe cardiomyopathy in human Chagas disease is due 
to a Th1-specific immune response. Infect Immun 71: 1185-1193.
Gomes JA, Campi-Azevedo AC, Teixeira-Carvalho A, Silveira-Lem-
os D, Vitelli-Avelar D, Sathler-Avelar R, Peruhype-Magalhães 
V, Silvestre KF, Batista MA, Schachnik NC, Correa-Oliveira R, 
Eloi-Santos S, Martins-Filho OA 2012. Impaired phagocytic ca-
pacity driven by downregulation of major phagocytosis-related 
cell surface molecules elicits an overall modulatory cytokine pro-
file in neutrophils and monocytes from the indeterminate clinical 
form of Chagas disease. Immunobiology 217: 1005-1016.
Gomes JA, Molica AM, Keesen TS, Morato MJ, de Araújo FF, Fares 
RC, Fiuza JA, Chaves AT, Pinheiro V, Nunes MC, Correa-Ol-
iveira R, Rocha MOC 2014. Inflammatory mediators from mono-
cytes down-regulate cellular proliferation and enhance cytokines 
production in patients with polar clinical forms of Chagas dis-
ease. Hum Immunol 75: 20-28.
Guedes PM, Gutierrez FR, Silva GK, Dellalibera-Joviliano R, Rodri-
gues GJ, Bendhack LM, Rassi Jr A, Rassi A, Schmidt A, Maciel 
BC, Marin Neto JA, Silva JS 2012. Deficient regulatory T-cell 
activity and low frequency of IL-17-producing T cells correlate 
with the extent of cardiomyopathy in human Chagas disease. 
PLoS Negl Trop Dis 6: e1630.
Gutierrez FR, Guedes PM, Gazzinelli RT, Silva JS 2009. The role 
of parasite persistence in pathogenesis of Chagas heart disease. 
Parasite Immunol 31: 673-685.
Krieger MA, Almeida E, Oelemann W, Lafaille JJ, Pereira JB, Krieg-
er H, Carvalho MR, Goldenberg S 1992. Use of recombinant an-
tigens for the accurate immunodiagnosis of Chagas disease. Am J 
Trop Med Hyg 46: 427-434.
Lafaille JJ, Linss J, Krieger MA, Souto-Padrón T, de Souza W, 
Goldenberg S 1989. Structure and expression of two Trypano-
soma cruzi genes encoding antigenic proteins bearing repetitive 
epitopes. Mol Biochem Parasitol 35: 127-136.
Lasso P, Mesa D, Cuéllar A, Guzmán F, Bolaños N, Rosas F, Velasco 
V, Thomas MC, Lopez MC, Gonzalez JM, Puerta CJ 2010. Fre-
quency of specific CD8+ T cells for a promiscuous epitope de-
rived from Trypanosoma cruzi KMP-11 protein in chagasic pa-
tients. Parasite Immunol 32: 494-502.
Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti 
R, Albareda MC, Lococo B, Postan M, Armenti A, Tarleton RL 
2009. Changes in Trypanosoma cruzi-specific immune responses 
after treatment: surrogate markers of treatment efficacy. Clin In-
fect Dis 49: 1675-1684.
Laucella SA, Postan M, Martin D, Fralish BH, Albareda MC, Al-
varez MG, Lococo B, Barbieri G, Viotti RJ, Tarleton RL 2004. 
Frequency of interferon-gamma-producing T-cells specific for 
Trypanosoma cruzi inversely correlates with disease severity in 
chronic human Chagas disease. J Infect Dis 189: 909-918.
Longhi SA, Atienza A, Prados GP, Buying A, Balouz V, Buscaglia 
CA, Santos R, Tasso LM, Bonato R, Chiale P, Pinilla C, Jud-
kowski VA, Gómez KA 2014. Cytokine production but lack of 
proliferation in peripheral blood mononuclear cells from chronic 
Chagas disease cardiomyopathy patients in response to T. cruzi 
ribosomal P proteins. PLoS Negl Trop Dis 8: e2906.
Lorena VM, Lorena IM, Braz SC, Melo AS, Melo MF, Melo MG, 
Silva ED, Ferreira AG, Morais CN, Costa VM, Correa-Oliveira 
R, Gomes YM 2010. Cytokine levels in serious cardiopathy of 
Chagas disease after in vitro stimulation with recombinant anti-
gens from Trypanosoma cruzi. Scand J Immunol 72: 529-539.
Marañón C, Egui A, Carrilero B, Thomas MC, Pinazo MJ, Gascón J, Se-
govia M, López MC 2011. Identification of HLA-A* 02:01-restricted 
CTL epitopes in Trypanosoma cruzi heat shock protein-70 recog-
nized by Chagas disease patients. Microbes Infect 13: 1025-1032.
Marchetti G, Merlini E, Sinigaglia E, Iannotti N, Bai F, Savoldi A, Tinca-
ti C, Carpani G, Bini T, Monforte AA 2012. Immune reconstitution 
in HIV+ subjects on lopinavir/ritonavir-based HAART according to 
the severity of pre-therapy CD4+. Curr HIV Res 10: 597-605.
Martin DL, Weatherly DB, Laucella SA, Cabinian MA, Crim MT, 
Sullivan S, Heiges M, Craven SH, Rosenberg CS, Collins MH, 
Sette A, Postan M, Tarleton RL 2006. CD8+ T-cell responses to 
Trypanosoma cruzi are highly focused on strain-variant trans-
sialidase epitopes. PLoS Pathog 2: e77.
Michailowsky V, Murta SM, Carvalho-Oliveira L, Pereira ME, Ferrei-
ra LR, Brener Z, Romanha AJ, Gazzinelli RT 1998. Interleukin-12 
T-cell responses in Chagas disease • María Cecilia Albareda, Susana Adriana Laucella 421
enhances in vivo parasiticidal effect of benznidazole during acute 
experimental infection with a naturally drug-resistant strain of 
Trypanosoma cruzi. Antimicrob Agents Chemother 42: 2549-2556.
Murta SM, Ropert C, Alves RO, Gazzinelli RT, Romanha AJ 1999. In-
vivo treatment with benznidazole enhances phagocytosis, parasite 
destruction and cytokine release by macrophages during infection 
with a drug-susceptible but not with a derived drug-resistant Try-
pansoma cruzi population. Parasite Immunol 21: 535-544.
Olivieri BP, Cotta-de-Almeida V, Araújo-Jorge T 2002. Benznidazole 
treatment following acute Trypanosoma cruzi infection triggers 
CD8+ T-cell expansion and promotes resistance to reinfection. 
Antimicrob Agents Chemother 46: 3790-3796.
Olivieri BP, de Souza AP, Cotta-de-Almeida V, de Castro SL, Araú-
jo-Jorge T 2006. Trypanosoma cruzi: alteration in the lymphoid 
compartments following interruption of infection by early acute 
benznidazole therapy in mice. Exp Parasitol 114: 228-234.
Rodrigues V, Cordeiro-da-Silva A, Laforge M, Ouaissi A, Akharid 
K, Silvestre R, Estaquier J 2014. Impairment of T-cell function in 
parasitic infections. PLoS Negl Trop Dis 8: e2567.
Romanha AJ, Alves RO, Murta SM, Silva JS, Ropert C, Gazzinelli RT 
2002. Experimental chemotherapy against Trypanosoma cruzi 
infection: essential role of endogenous interferon-gamma in me-
diating parasitologic cure. J Infect Dis 186: 823-828.
Samudio M, Montenegro-James S, Cabral M, Martinez J, de Arias 
AR, James MA 1998. Cytokine responses in Trypanosoma cruzi-
infected children in Paraguay. Am J Trop Med Hyg 58: 119-121.
Sathler-Avelar R, Vitelli-Avelar DM, Elói-Santos SM, Gontijo ED, 
Teixeira-Carvalho A, Martins-Filho OA 2012. Blood leukocytes 
from benznidazole-treated indeterminate Chagas disease pa-
tients display an overall type-1-modulated cytokine profile upon 
short-term in vitro stimulation with Trypanosoma cruzi antigens. 
BMC Infect Dis 12: 123.
Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana 
M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho 
OA 2006. Benznidazole treatment during early-indeterminate 
Chagas disease shifted the cytokine expression by innate and 
adaptive immunity cells toward a type 1-modulated immune pro-
file. Scand J Immunol 64: 554-563.
Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, de Lana M, Dias 
JCP, Teixeira-Carvalho A, Elói-Santos SM, Martins-Filho OA 
2008. Etiological treatment during early chronic indeterminate 
Chagas disease incites an activated status on innate and adaptive 
immunity associated with a type 1-modulated cytokine pattern. 
Microbes Infect 10: 103-113.
Seder RA, Darrah PA, Roederer M 2008. T-cell quality in memory 
and protection: implications for vaccine design. Nat Rev Immunol 
8: 247-258.
Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yam-
potis C 1998. Efficacy of chemotherapy with benznidazole in 
children in the indeterminate phase of Chagas disease. Am J Trop 
Med Hyg 59: 526-529.
Tarleton RL 2003. Chagas disease: a role for autoimmunity? Trends 
Parasitol 19: 447-451.
Viotti R, Vigliano C, Alvarez MG, Lococo B, Petti M, Bertocchi G, 
Armenti A, de Rissio AM, Cooley G, Tarleton R, Laucella S 2011. 
Impact of aetiological treatment on conventional and multiplex se-
rology in chronic Chagas disease. PLoS Negl Trop Dis 5: e1314.
Viotti R, Vigliano C, Armenti H, Segura E 1994. Treatment of chronic 
Chagas disease with benznidazole: clinical and serologic evolution 
of patients with long-term follow-up. Am Heart J 127: 151-162.
Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi 
G, Armenti A 2009. Side effects of benznidazole as treatment 
in chronic Chagas disease: fears and realities. Expert Rev Anti 
Infect Ther 7: 157-163.
Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, 
Postan M, Armenti A 2006. Long-term cardiac outcomes of treat-
ing chronic Chagas disease with benznidazole versus no treat-
ment: a nonrandomized trial. Ann Intern Med 144: 724-734.
Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, Alvarez MG, 
Armenti A 2005. Clinical predictors of chronic chagasic myo-
carditis progression. Rev Esp Cardiol 58: 1037-1044.
Virgin HW, Wherry EJ, Ahmed R 2009. Redefining chronic viral in-
fection. Cell 138: 30-50.
WHO - World Health Organization 2015. Chagas disease (American 
trypanosomiasis). Available from: who.int/mediacentre/fact-
sheets/fs340/en/.
Zulantay I, Honores P, Solari A, Apt W, Ortiz S, Osuna A, Rojas A, 
López B, Sánchez G 2004. Use of polymerase chain reaction 
(PCR) and hybridization assays to detect Trypanosoma cruzi in 
chronic chagasic patients treated with itraconazole or allopurinol. 
Diagn Microbiol Infect Dis 48: 253-257.
